Distinguished in Hemolytic Anemia

Rong F. Fu

No. 154, Anshan Road, 
Xiaobailou, CN 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Hemolytic Anemia
No. 154, Anshan Road, 
Xiaobailou, CN 
OverviewLocationsClinical Research

Overview

Rong Fu practices in Xiaobailou, China. Fu is rated as a Distinguished expert by MediFind in the treatment of Hemolytic Anemia. Their top areas of expertise are Aplastic Anemia, Anemia, Paroxysmal Cold Hemoglobinuria, Splenectomy, and Lymphadenectomy.

Their clinical research consists of co-authoring 568 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 47 articles in the study of Hemolytic Anemia.

Locations

No. 154, Anshan Road, Xiaobailou, 300052, China
Other Locations
154 Anshan Street, Tianjin, 300052, China
154 Anshan Road, Tianjin, China
No.19 Yuquan Road, Shijingshan, 100049, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Single-arm, Pivotal Registration Phase II Study of the Efficacy and Safety of APG-2575 Monotherapy in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Single-arm, Pivotal Registration Phase II Study of the Efficacy and Safety of APG-2575 Monotherapy in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment Status: Recruiting
Publish Date: January 23, 2024
Intervention Type: Drug
Study Drug: APG2575
Study Phase: Phase 2
A National, Prospective, Non-interventional Study of NINLARO in Real World Clinical Practice
A National, Prospective, Non-interventional Study of NINLARO in Real World Clinical Practice
Enrollment Status: Active_not_recruiting
Publish Date: April 10, 2025
A Phase III Randomized, Controlled, Multicenter, Open-label Study of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase III Randomized, Controlled, Multicenter, Open-label Study of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment Status: Active_not_recruiting
Publish Date: February 11, 2025
Intervention Type: Combination product
Study Drugs: Selinexor+Bortezomib+Dexamethasone, Bortezomib+Dexamethasone
Study Phase: Phase 3
A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia
A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia
Enrollment Status: Completed
Publish Date: October 28, 2024
Intervention Type: Drug
Study Drugs: Azacitidine, Pevonedistat
Study Phase: Phase 3
A Multicenter, Open-label, Phase 1/2a Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
A Multicenter, Open-label, Phase 1/2a Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Enrollment Status: Completed
Publish Date: April 15, 2024
Intervention Type: Drug
Study Drugs: TJ011133, Azacitidine
Study Phase: Phase 1/Phase 2
A Single-arm, Open-label, Multi-center Phase Ib/II Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL)
A Single-arm, Open-label, Multi-center Phase Ib/II Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL)
Enrollment Status: Terminated
Publish Date: November 29, 2023
Intervention Type: Drug
Study Drug: TQ-B3525
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

568 Total Publications

Development, reliability, and validity of a treatment-related quality of life scale for Chinese patients with multiple myeloma
Development, reliability, and validity of a treatment-related quality of life scale for Chinese patients with multiple myeloma
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: October 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Fu's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 13 Advanced Conditions
View All 81 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile